Envveno Medical Corp Stock Alpha and Beta Analysis
| NVNO Stock | USD 10.01 1.92 16.09% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as enVVeno Medical Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in EnVVeno Medical over a specified time horizon. Remember, high EnVVeno Medical's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to EnVVeno Medical's market risk premium analysis include:
Beta 2.54 | Alpha (1.19) | Risk 8.01 | Sharpe Ratio (0.14) | Expected Return (1.11) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out EnVVeno Medical Analysis, EnVVeno Medical Valuation, EnVVeno Medical Correlation, EnVVeno Medical Hype Analysis, EnVVeno Medical Volatility, EnVVeno Medical Price History and analyze EnVVeno Medical Performance. EnVVeno Medical Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. EnVVeno Medical market risk premium is the additional return an investor will receive from holding EnVVeno Medical long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in EnVVeno Medical. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate EnVVeno Medical's performance over market.| α | -1.19 | β | 2.54 |
EnVVeno Medical expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of EnVVeno Medical's Buy-and-hold return. Our buy-and-hold chart shows how EnVVeno Medical performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.EnVVeno Medical Market Price Analysis
Market price analysis indicators help investors to evaluate how EnVVeno Medical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading EnVVeno Medical shares will generate the highest return on investment. By understating and applying EnVVeno Medical stock market price indicators, traders can identify EnVVeno Medical position entry and exit signals to maximize returns.
EnVVeno Medical Return and Market Media
The median price of EnVVeno Medical for the period between Mon, Nov 3, 2025 and Sun, Feb 1, 2026 is 12.25 with a coefficient of variation of 35.29. The daily time series for the period is distributed with a sample standard deviation of 5.19, arithmetic mean of 14.71, and mean deviation of 4.24. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve | 11/13/2025 |
2 | enVVeno Medical Corporation stock retracement recovery analysis - 2025 Fundamental Recap Community Driven Trade Alerts - newser.com | 11/17/2025 |
3 | enVVeno Medical to Participate in a Live Virtual Investor CEO Connect Segment | 11/26/2025 |
4 | enVVeno Medical adds reverse stock split vote to 2025 meeting - Stock Titan | 12/02/2025 |
5 | Disposition of 4900 shares by Duhay Francis of EnVVeno Medical at 0.3556 subject to Rule 16b-3 | 12/11/2025 |
6 | enVVeno Medical Holds Annual Stockholders Meeting - TipRanks | 12/12/2025 |
7 | Disposition of 100000 shares by Glickman Marc H. of EnVVeno Medical subject to Rule 16b-3 | 12/16/2025 |
8 | 12 Health Care Stocks Moving In Fridays After-Market Session | 12/19/2025 |
9 | Acquisition by Jenusaitis Matthew of 8403 shares of EnVVeno Medical subject to Rule 16b-3 | 12/26/2025 |
10 | Acquisition by Duhay Francis of 5673 shares of EnVVeno Medical subject to Rule 16b-3 | 01/16/2026 |
11 | Acquisition by Hamed Alavi of 100000 shares of EnVVeno Medical at 3.59 subject to Rule 16b-3 | 01/27/2026 |
12 | Highs Report Is enVVeno Medical Corporation trading at a discount - 2025 Support Resistance Long Hold Capital Preservation Tips - baoquankhu1.vn | 01/29/2026 |
About EnVVeno Medical Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including EnVVeno or other stocks. Alpha measures the amount that position in enVVeno Medical Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Payables Turnover | 0.47 | 0.58 | Days Of Inventory On Hand | 31.06 | 27.61 |
EnVVeno Medical Upcoming Company Events
As portrayed in its financial statements, the presentation of EnVVeno Medical's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, EnVVeno Medical's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of EnVVeno Medical's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of EnVVeno Medical. Please utilize our Beneish M Score to check the likelihood of EnVVeno Medical's management manipulating its earnings.
| 25th of January 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with EnVVeno Medical
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out EnVVeno Medical Analysis, EnVVeno Medical Valuation, EnVVeno Medical Correlation, EnVVeno Medical Hype Analysis, EnVVeno Medical Volatility, EnVVeno Medical Price History and analyze EnVVeno Medical Performance. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
EnVVeno Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.